Overview

A Study to Assess the Safety, Pharmacokinetics and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to characterize the safety and pharmacokinetic (PK) profile of UCB6114 administered as monotherapy or in combination with selected standard of care (SOC) regimens.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

UCB Biopharma S.P.R.L.
UCB Biopharma SRL

Treatments:

Fluorouracil
Leucovorin
Trifluridine